Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2015 - 2026)

Protagonist Therapeutics has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $407000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 70.29% year-over-year to $407000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 74.67% YoY) and the FY2025 annual result came in at $1.3 million, up 54.96% from the prior year.
• Depreciation & Amortization (CF) rose to $407000.0 in Q1 2026 per PTGX's latest filing, from $376000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $407000.0 in Q1 2026 and troughed at $118000.0 in Q4 2024.
• A 5-year average of $266117.6 and a median of $248000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) slumped 52.42% in 2024, then jumped 218.64% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $256000.0 in 2022, then slipped by 3.12% to $248000.0 in 2023, then plunged by 52.42% to $118000.0 in 2024, then surged by 218.64% to $376000.0 in 2025, then increased by 8.24% to $407000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $407000.0, $376000.0, and $361000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.